Ronald Asbury Andrews

Chief Executive Officer, CLARIENT, INC.

Companies

Plus TherapeuticsBoard member Mar 30, 2026 to now¹
Precipio, Inc.Board member Mar 4, 2021 to now²
Insight Molecular Diagnostics Inc.Chief executive officer Jul 3, 2019 to Dec 9, 2022³
Insight Molecular Diagnostics Inc.Board member Apr 12, 2018 to Dec 9, 2022⁴
Insight Molecular Diagnostics Inc.President Apr 1, 2020 to Aug 18, 2022⁵
Life TechnologiesPresident Feb 2, 2012 to Feb 4, 2014⁶

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Jul 1, 2026Exercised options 922 shares of Plus Therapeutics⁹
Oct 15, 2025Granted 568 shares at $17.58 of Precipio, Inc.¹⁰
Oct 15, 2025Granted 568 shares at $17.58 of Precipio, Inc.⁸
Jul 16, 2025Granted 676 shares at $14.78 of Precipio, Inc.¹¹
Apr 15, 2025Granted 1,785 shares at $5.60 of Precipio, Inc.¹²
Jan 15, 2025Granted 1,639 shares at $6.10 of Precipio, Inc.¹³
Oct 15, 2024Granted 1,510 shares at $6.62 of Precipio, Inc.¹⁴
Jul 15, 2024Granted 2,157 shares at $4.63 of Precipio, Inc.¹⁵
Apr 15, 2024Granted 3,153 shares at $6.66 of Precipio, Inc.¹⁶
Oct 24, 2023Granted 4,005 shares of Precipio, Inc.¹⁷
Sep 12, 2023Granted 6,060 shares of Precipio, Inc.¹⁸
Dec 1, 2022Exercised options 250,000 shares of Insight Molecular Diagnostics Inc.⁷
Aug 16, 2022Bought 40,000 shares at $0.96 of Insight Molecular Diagnostics Inc.¹⁹
Mar 16, 2022Bought 50,000 shares at $1.28 of Insight Molecular Diagnostics Inc.²⁰

The numbers on this page point here. Each one links to the record it came from.